NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-23-051 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-292 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings.
Funding Opportunity RFA-DK-23-515 from the NIH Guide for Grants and Contracts. The purpose of this limited competition notice of funding opportunity (NOFO) is to continue the support of the Clinical Sites of the NASH Clinical Research Network (NASH CRN) as they complete active clinical treatment trials and continue to longitudinally gather biospecimens and data of children and adults with nonalcoholic fatty liver disease (NAFLD), including steatosis, steatohepatitis, and cirrhosis (NAFLD database study). The NASH CRN has been sponsored by the NIDDK since 2002, and renewed in 2009 and 2014. Research in the NASH CRN has been focused on the etiology, contributing factors, natural history, complications, and therapy of nonalcoholic steatohepatitis.
Notice NOT-AI-23-066 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-170 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-173 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-24-035 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications to continue critical ongoing network and infrastructure support for advancing development in a specific high-priority area of behavioral and social research on Alzheimers disease (AD) and AD-related dementias (ADRD): The Harmonized Cognitive Assessment Protocol (HCAP) International AD/ADRD Research Network. Network/infrastructure-building activities include but are not limited to meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots to test or tailor measures in new populations or contexts; development of guidance on selected topics such as biomarkers, diagnosis and classification of dementia, protocol development, fieldwork challenges, statistical harmonization, and analytic methods; educational activities such as intensive summer institutes, series of workshops and related network activities, or advanced seminars on methodology; dissemination and outreach activities; and coordinate activities with other related networks on AD/ADRD.
Funding Opportunity RFA-AG-24-034 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications to renew critical ongoing network and infrastructure support for advancing development of specific high-priority areas of behavioral and social?research on aging in the following priority areas: (1) Stress Measurement, (2) Life Course Health Disparities at Older Ages, (3) Aging Research on Criminal Justice and Health Disparities, (4) Rural Aging, (5) Genomics of Behavioral and Social Science, (6) Behavioral and Social Research on Aging in Animal Models. Network infrastructure is designed to build resources for advancing aging-relevant research in the field at large; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs to foster transdisciplinary integration in aging research, as recommended by the 2019 Division of Behavioral and Social Research (BSR) National Advisory Council on Aging (NACA) Review Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots to develop data, theoretical frameworks, empirical methods, etc.; dissemination and outreach activities; and educational activities such as intensive summer institutes, series of workshops and related network activities, advanced seminars on methodology, or short-term residential opportunities.
Funding Opportunity RFA-AG-24-033 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites applications for a State Dementia Care Research Center (henceforth Center) which aims to ultimately improve care for persons living with dementia (PLWD) and their caregivers/care partners by building a research evidence base that can be used to improve dementia care coordination, integration, and care transitions in community settings, as well as inform policymaking. With recognition of the differences in provision, coverage, and access to Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) care across the nation, this infrastructure resource will support research on social services and health systems within states. Specifically, the new resource will invite: (1) research on AD/ADRD care coordination, integration, and transitions within states; (2) the creation and integration of data on home and community-based services and health care data within states; and (3) support the dissemination of findings to stakeholders, the public, and policymakers. The Center will directly address AD/ADRD research implementation milestones on care integration with emphasis on healthcare disparities and policy by creating a consortium of scholars who will study AD/ADRD care coordination across settings, accounting for state-level and sub-state level heterogeneity in provision, coverage, and access to services.
Notice NOT-OD-23-175 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-24-015 from the NIH Guide for Grants and Contracts. The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.
Funding Opportunity RFA-HL-24-016 from the NIH Guide for Grants and Contracts. The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.
Notice NOT-NS-23-108 from the NIH Guide for Grants and Contracts
Notice NOT-EY-23-009 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-168 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-051 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-115 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-114 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-107 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-24-023 from the NIH Guide for Grants and Contracts. To enable the development and validation of real-world remote digital endpoints from wearable devices for monitoring pain experience and progression, response to interventions, and impact on quality of life. In the context of this RFA, endpoints will include biosignatures derived from functional and physiological assessments detected from wearable devices. These biosignatures can be used to monitor the effects of therapeutics developed for the treatment of pain.